(S020) The Role of Adjuvant Radiotherapy in T4 Colon Cancer
In this large population dataset, adjuvant radiation was associated with an improvement in OS in a modern cohort of patients. Patients with distal tumors, higher-grade disease, negative lymph nodes, and larger tumors may derive a greater benefit with radiation.
Talha Shaikh, MD, Thomas M. Churilla, MD, Colin T. Murphy, MD, Michael Hall, MD, MS, Elin R. Sigurdson, MD, PhD, Joshua E. Meyer, MD; Fox Chase Cancer Center
BACKGROUND: The role of adjuvant radiation for T4 colon adenocarcinoma is controversial. We assessed the impact of adjuvant radiation on treatment outcomes in a large national dataset.
MATERIALS AND METHODS: The Surveillance, Epidemiology, and End Results (SEER) registry was queried from 1988–2012 for patients aged > 18 years diagnosed with T4 colon adenocarcinoma who underwent curative surgery. The primary endpoints were overall survival (OS) and cancer-specific survival (CSS) for patients treated with or without adjuvant radiation. Survival was assessed utilizing the Kaplan-Meier method and a Cox proportional hazards model.
RESULTS: A total of 29,830 patients were identified; 1,877 (6.3%) patients received adjuvant radiation. There was no difference in OS (P = .384) with adjuvant radiation. Patients receiving radiation had a worse CSS than patients who received no adjuvant radiation (P < .001). On examination of a modern cohort of patients treated from 2004–2012, patients receiving adjuvant radiation had an improvement in OS compared with patients receiving no radiation (P < .001), and there was a trend toward improved CSS in patients receiving adjuvant radiation (P = .053). On multivariable analysis, adjuvant radiation remained associated with OS (hazard ratio [HR], 0.88 [95% CI, 0.78–0.99]; P = .034). Subgroup analysis demonstrated an OS benefit with radiation in patients with distal tumors (P = .002), grade 3/4 disease (P = .006), grade 2 disease (P = .012), negative lymph nodes (P < .001), and tumor size > 5 cm (P < .001).
CONCLUSION: In this large population dataset, adjuvant radiation was associated with an improvement in OS in a modern cohort of patients. Patients with distal tumors, higher-grade disease, negative lymph nodes, and larger tumors may derive a greater benefit with radiation.
Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
